Previous studies have demonstrated that lymphoma cells can unlock this oncogenic strategy through CD79B/A mutations, which result in increased BCR surface levels through hindered BCR internalization and loss of negative regulation by phosphorylation by LYN (10). This evidence concerns the gene BCR and lymphoma.